Becton Dickinson & Co. closed 10.30% short of its 52-week high of $251.99, which the company reached on February 3rd.

The Financial Times reports today that BD (NYSE: BDX) began discussions with competitors for the sale of its Life Sciences ...

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment ...

and BD Interventional. Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” ...

The Food and Drug Administration has identified a Class I recall of Becton, Dickinson and Company BD Alaris Systems Manager and BD Care Coordination Engine Infusion Adapters due to reports that ...

Becton Dickinson (BDX) announced the first patient treated in an investigational device exemption clinical trial intended to advance BD’s ...

BD treated the first subject in the trial with GalaFLEX LITE Scaffold for reducing the recurrence of CC during breast revision surgeries.